Insempra
Almost everything we use daily — from food to clothing to toys — relies on decades- to centuries-old ingredients and production processes that constitute the $4 trillion chemical petroleum industry. As the naturally occurring planetary resources to support our lives get more scarce and many production processes are toxic, it is time to rethink how we produce the goods and materials required to support human life. As a second generation synthetic biology platform, Insempra plans to leverage recent advances across the synbio toolstack, including computational R&D tools and advanced contract manufacturing infrastructure, to build out an asset-light biomanufacturing platform that will enable faster R&D iteration and the ability to rapidly produce complex molecules for ingredients and materials used in industrial, consumer and pharma applications — with significantly less energy requirements and waste produced than traditional chemical industrialization processes today. This enables a world where e.g. cosmetics and materials are made out of bio-compounds versus toxic petrochemical derivatives.
Our Thesis
As consumer pressure accelerates the push to transform (for sustainability) and decarbonize today’s destructive chemical industry, Insempra has a chance to become the fabric for an entirely new and sustainable way to develop most consumer goods such as cosmetics, fashion, fabric, food and more — while potentially opening up entirely new markets based on novel bio-materials. Moreover, Insempra’s team have backgrounds in scaling production and go-to-market of synthetic biology products from companies like AMSilk, Clariant, Evonik, Fresenius and Syngenta. By closely collaborating with downstream supply chain companies and brands directly, Insempra could be a key component of economies stepping up to meet growing sustainability requirements in materials production for a fast-growing base of consumers already buying — and demanding more — eco-friendly products.
We’re excited to be backing Jens Klein and the entire Insempra team on their mission. Here is a Forbes article with a few more details.
—
Disclaimer: The information contained in this article has been prepared solely for informational purposes and is not an offer to sell or a solicitation of an offer to purchase an interest in any entity managed by BlueYard Capital (“BlueYard”). Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold, or directly invest in the company or its securities. It may not be modified, reproduced, or redistributed in whole or in part without the prior written consent of BlueYard. Portfolio company information presented herein is for informational purposes only and not intended to be a guarantee of certain investment results. BlueYard does not represent that the information herein is accurate, true, or complete, makes no warranty, express or implied, regarding the information herein and shall not be liable for any losses, damages, costs, or expenses relating to its adequacy, accuracy, truth, completeness, or use. All other company, product and service names or service marks of others and their use does not imply their endorsement of, or an association with this program.
